• <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
      <b id="1ykh9"><small id="1ykh9"></small></b>
    1. <b id="1ykh9"></b>

      1. <button id="1ykh9"></button>
        <video id="1ykh9"></video>
      2. west china medical publishers
        Author
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Author "王永波" 2 results
        • Current status of postoperative specific quality of life and its influencing factors analysis for patients with thyroid cancer

          ObjectiveTo investigate the quality of life (QoL) of patients with differentiated thyroid cancer (DTC) after surgery and analyze its relevant influencing factors. MethodsThe patients with DTC who underwent surgical resection in the First Affiliated Hospital of Zhengzhou University from December 1, 2021 to October 1, 2023 were investigated through the postoperative follow-up platform and follow-up management group. The postoperative QoL of DTC patients were evaluate using the Chinese version of the Thyroid Cancer Specific Quality of Life Questionnaire (THYCA-QoL) specific scale and the Chinese version of the European Organization for Research and Treatment of Cancer (EORTC) developed a quality of life questionnaire consisting of 30 items (QLQ-C30). The higher overall average score of THYCA-QoL scale, the more clinical symptoms of patients, namely the negative QoL. The higher the EORTC QLQ-C30 overall health status score, the better QoL. In addition, multiple linear regression was used to explore the risk factors affecting the postoperative specific QoL score of DTC patients. ResultsA total of 1 076 patients’ questionnaires were collected. The EORTC QLQ-C30 overall health status score of 1 076 patients was 67±22 and the THYCA-QoL overall score was 22±13. The results of multivariate linear regression analysis showed that the early postoperative period (<6 months), male, age, without postoperative lifetime medication and without postoperative iodine-131 radiotherapy had negative effects on the overall score of THYCA-QoL scale (P<0.05), meanwhile the early postoperative period (<6 months) or later (≥12 months), without postoperative lifetime medication and without postoperative iodine-131 radiotherapy had positive effects on the overall health status score of EORTC QLQ-C30 (P<0.05). ConclusionsEORTC QLQ-C30 combined with THYCA-QoL can evaluate not only the common symptoms of cancer, but also the specific symptoms of thyroid cancer after surgery. And understanding the factors affecting the QoL of patients with thyroid cancer after surgery could provide targeted and supportive treatment and nursing for discharged patients to improve the QoL of patients with thyroid cancer after surgery.

          Release date:2024-08-30 06:05 Export PDF Favorites Scan
        • 地塞米松聯合用藥方案在原發性甲狀腺功能亢進患者術前準備中的臨床實踐經驗

          目的探討地塞米松聯合用藥方案在原發性甲狀腺功能亢進癥(簡稱 “甲亢” )患者術前準備中應用的效果。方法回顧性收集鄭州大學第一附屬醫院甲狀腺外科2021年1月1日至2022年10月1日期間收治的原發性甲亢手術患者。采用地塞米松聯合碘劑和β-受體阻滯劑聯合應用的7 d術前準備方案(簡稱 “7 d方案” ):連續口服7 d復方碘溶液(3次/d,0.75 mL/次),在口服復方碘溶液的第5、6、7天時同時加用地塞米松注射液緩慢靜脈滴注(1次/d,20 mg/次,上午10∶00開始,每次輸入間隔時間24 h),手術前1 d口服β-受體阻滯劑普萘洛爾(劑量因人而異),于術前準備完成后第2天(第8天時)手術。觀察入院時及使用地塞米松后的第1、2、3、4、5天時血清促甲狀腺激素、游離三碘甲狀腺原氨酸(free triiodothyronine,FT3)及游離甲狀腺素(free thyroxine,FT4)水平的變化情況以及并發癥情況。結果本研究共收集到58例患者,使用地塞米松后第1、2、3、4、5天時的FT3及FT4水平總體一直呈持續下降趨勢(F=88.355,P<0.001;F=21.291,P<0.001),并且使用地塞米松后第2天開始FT3均值一直維持在正常水平,FT4均值雖未完全達到正常水平但比較接近正常水平;促甲狀腺激素水平總體比較差異無統計學意義(χ2=1.607,P=0.900)。術后未發生甲狀腺危象。結論從本研究結果看,“7 d方案”進行術前準備,較傳統術前準備方法縮短了術前準備時間,對原發性甲亢的圍術期管理安全、有效。

          Release date:2023-03-22 09:25 Export PDF Favorites Scan
        1 pages Previous 1 Next

        Format

        Content

      3. <xmp id="1ykh9"><source id="1ykh9"><mark id="1ykh9"></mark></source></xmp>
          <b id="1ykh9"><small id="1ykh9"></small></b>
        1. <b id="1ykh9"></b>

          1. <button id="1ykh9"></button>
            <video id="1ykh9"></video>
          2. 射丝袜